

Dithiocarbamate promoted practical synthesis of *N*-Aryl-2-aminobenzazoles: Synthesis of novel Aurora-A kinase inhibitor

NARESH KUMAR KATARI*, M VENKATANARAYANA and KUMMARI SRINIVAS

Department of Chemistry, HTP Campus, GITAM University, Rudraram, Hyderabad, Telangana 502 329, India
e-mail: dr.n.k.katari@gmail.com

MS received 18 June 2014; revised 24 July 2014; accepted 10 August 2014

Abstract. Various *N*-aryl-2-aminobenzoxazoles and *N*-aryl-2-aminobenzothiazoles were synthesized from *o*-aminophenol and *o*-aminothiophenol, respectively, mediated by dithiocarbamate in one step. The salient features of this method include mild reaction condition, high yield and large scale synthesis. Application of this methodology has been demonstrated by synthesizing potent Aurora kinase-A inhibitors.

Keywords. 2-Aminobenzoxazole; 2-Aminobenzothiazole; Dithiocarbamate; 4-Aminoquinazoline Aurora kinase.

1. Introduction

Benzo-1, 3-diazoles are a biologically important class of molecules and are widely used as pharmaceutical agents. Interestingly, during the structure activity relationship (SAR) studies it was observed that the change of the structure of substituent group at C-2 position commonly results in change of its bioactivity. 2-substituted benzoxazoles, particularly *N*-aryl-2-aminobenzoxazole derivatives, have been or are currently under investigation for the treatment of a wide variety of disorders such as HIV,¹ neuro degeneration² and inflammatory diseases.³ Moreover, 2-aminobenzoxazoles have also been reported as VEGFR inhibitors and are thus important for hyper proliferative diseases such as cancer and rheumatoid arthritis.⁴ The 2-aminobenzothiazole compounds were mostly synthesized as kinase inhibitors in recent times. For example, the investigations of 2-amino benzothiazole as a key pharmacore led to new drugs such as the p56lck inhibitor⁵ and p38 α MAP kinase inhibitor.⁶ Also, selective targeting T-and B-cell lymphomas by 2-aminobenzothiazole moiety has been reported.⁷

Therefore, an efficient and practical method for the synthesis of a diverse collection of *N*-aryl-2-aminobenzazoles would be of great value for drug discovery. The most common method for the synthesis of 2-aminobenzoxazoles is through the cyclodesulfurization of *N*-substituted-2-hydroxy phenyl-thioureas.

Thiourea intermediates are easily derived from the condensation of an appropriately substituted

o-aminophenol and any of a number of synthetically or commercially available arylisothiocyanates.⁸ Several cyclodesulfurization methods have appeared in the literature. Procedures, which incorporate reagents such as HgO,⁹ NiO₂,¹⁰ and LiOH/H₂O₂¹¹ and 1, 1'-(ethane-1,2-diyl)dipyridinium bistribromide (EDPBT)¹² have been reported.

Further, transition metal-catalyzed (particularly palladium, copper and iron) intramolecular cyclisation of 2-bromobenzothioureas is the most common method for the synthesis of *N*-aryl-2-aminobenzo- thiazoles.¹³ Synthesis of 2-aminobenzothiazoles *via* intramolecular C-S bond formation/C-H bond functionalization utilizing a co-catalytic system has been reported.¹⁴

However, the utility and applicability of these reactions are limited due to toxic metals, expensive catalyst system and pre-functionalization of the starting material. Apart from these, the synthesis of isothiocyanates requires the use of toxic thiophosgene.

Moreover, a disadvantage with isothiocyanates is that they are unstable if stored for long periods. These drawbacks make the presently available methodologies difficult for large in scale industrial application. The present studies to the development of a new route for the synthesis of organic compounds and our interest remains in dithiocarbamate mediated reactions.¹⁵

2. Experimental

2.1 General experimental

A mixture of *o*-aminophenol/*o*-aminothiophenol (1.0 eq), dithiocarbamate (1.2 eq), and K₂CO₃ (3.0 eq)

*For correspondence

in dry DMF (10–15 mL) in 50 mL rb flask connected to a reflux condensor was refluxed for 2 h. Progress of the reaction was monitored by TLC. The reaction mixture was filtered through celite. The filtrate was concentrated in vacuo and the resulting mixture chromatographed on silica gel (DCM:MeOH) to yield *N*-aryl-2-aminobenzazoles.

2.2 Experimental data

2.2a Benzooxazol-2-yl-phenyl-amine (table 1, Entry 1): Light brown solid; M.p.: 142–143°C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.60 (br s, 1H, NH), 7.75 (d, *J* = 7.76 MHz, 2H), 7.44 (t, *J* = 7.96 Hz, 2H), 7.38–7.32 (m, 2H), 7.21 (t, *J* = 7.47 Hz, 1H), 7.12 (t, *J* = 7.62 Hz, 1H), 7.03 (t, *J* = 7.32 Hz, 1H); Mass (ESI): 211.0 [M+H]⁺.

2.2b Benzothiazol-2-yl-phenyl-amine (table 1, Entry 2): Colourless solid; M.p.: 166–167°C; IR (KBr, cm^{−1}): 3444, 3054, 1666, 1573, 1467, 1249; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.46 (br s, 1H, NH), 7.81–7.78 (m, 3H), 7.61–7.59 (m, 1H), 7.38–7.30 (m, 3H), 7.17–7.14 (m, 1H), 7.04–7.00 (m, 1H); ¹³C NMR (50 MHz, DMSO-*d*₆): δ 161.92, 152.46, 140.98, 130.33, 129.34, 126.21, 122.62, 122.40, 121.39, 119.56, 118.11; Mass (ESI): 227.2 [M+H]⁺.

2.2c Benzooxazol-2-yl-(3-chloro-phenyl)-amine (table 1, Entry 3): Yellow solid; M.p.: 212–213°C; IR (KBr, cm^{−1}): 3444, 3032, 1663, 1576, 1492, 1231, 1092; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.50 (br s, 1H, NH), 8.15–8.13 (m, 1H), 7.65–7.61 (m, 1H), 7.45–7.05 (m, 6H); Mass (ESI): 244.9 [M+H]⁺.

2.2d Benzothiazol-2-yl-(3-chloro-phenyl)-amine (table 1, Entry 4): solid; M.p.: 237–238°C; IR (KBr, cm^{−1}): 3444, 3117, 1620, 1493, 1275, 1098, 730; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.61 (br s, 1H, NH), 7.81 (d, *J* = 8.64 Hz, 3H), 7.60 (d, *J* = 7.92 Hz, 1H), 7.40 (d, *J* = 8.76 Hz, 2H), 7.32 (t, *J* = 7.28 Hz, 1H), 7.16 (t, *J* = 7.44 Hz, 1H); Mass (ESI): 261.0 [M+H]⁺.

2.2e Benzooxazol-2-yl-(4-fluoro-phenyl)-amine (table 1, Entry 5): solid; M.p.: 112–113°C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.62 (br s, 1H, NH), 7.77–7.73 (m, 2H), 7.47–7.41 (m, 2H), 7.22–7.09 (m, 4H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 158.63, 158.00, 156.26, 147.00, 135.15, 123.98, 121.64, 119.18, 119.10, 116.54, 115.64, 115.41, 108.92; Mass (ESI): 228.8 [M+H]⁺.

2.2f Benzothiazol-2-yl-(4-fluoro-phenyl)-amine (table 1, Entry 6): solid; M.p.: 212–213°C; IR (KBr, cm^{−1}):

3443, 3077, 1626, 1574, 1210; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.49 (br s, 1H, NH), 7.80–7.78 (m, 3H), 7.57 (d, *J* = 7.88 Hz, 1H), 7.31 (t, *J* = 7.56 Hz, 1H), 7.22–7.12 (m, 3H); Mass (ESI): 245.0 [M+H]⁺.

2.2g Benzooxazol-2-yl-(4-methoxy-phenyl)-amine (table 1, Entry 7): solid; M.p.: 137–139°C; IR (KBr, cm^{−1}): 3383, 3043, 2836, 1674, 1579, 1510, 1232, 1031; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.60 (br s, 1H, NH), 7.50 (d, *J* = 8.60 Hz, 1H), 7.30–7.10 (m, 4H), 6.91–6.78 (m, 3H), 3.85 (s, 3H); Mass (ESI): 241.0 [M+H]⁺.

2.2h Benzothiazol-2-yl-(4-methoxy-phenyl)-amine (table 1, Entry 8): solid; M.p.: 166–167°C; IR (KBr, cm^{−1}): 3451, 3184, 2902, 1619, 1567, 1510, 1455, 1251, 1030; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.25 (br s, 1H, NH), 7.75 (d, *J* = 7.64 Hz, 1H), 7.66 (d, *J* = 8.6 Hz, 2H), 7.53 (d, *J* = 7.84 Hz, 1H), 7.28 (t, *J* = 7.4 Hz, 1H), 7.10 (t, *J* = 7.4 Hz, 1H), 6.94 (d, *J* = 8.68 Hz, 2H), 3.73 (s, 3H); Mass (ESI): 255.1 [M+H]⁺.











































2.2i Benzooxazol-2-yl-(2,3-dimethyl-phenyl)-amine (table 1, Entry 9): solid; M.p.: 140–141°C; IR (KBr, cm^{−1}): 3445, 3146, 2852, 1664, 1580, 1473, 1264; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.22 (s, 1H), 7.78–7.75 (m, 1H), 7.40–7.38 (m, 1H), 7.25–7.17 (m, 4H), 7.09–7.05 (m, 1H), 2.36 (s, 3H), 2.28 (s, 3H); ¹³C NMR (50 MHz, DMSO-*d*₆): δ 160.53, 148.03, 143.17, 137.53, 137.03, 130.39, 126.74, 125.93, 124.13, 122.16, 121.20, 116.34, 109.05, 20.57, 14.19;

2.2j Benzothiazol-2-yl-(2,3-dimethyl-phenyl)-amine (table 1, Entry 10): solid; M.p.: 196–197°C; IR (KBr, cm^{−1}): 3440, 3134, 2849, 1613, 1569, 1450; ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.67 (br s, 1H, NH), 7.70 (d, *J* = 7.68 Hz, 1H), 7.44 (dd, *J* = 7.68, 7.89 Hz, 2H), 7.24 (t, *J* = 7.52 Hz, 1H), 7.14–7.03 (m, 3H), 2.27 (s, 3H), 2.15 (s, 3H); Mass (ESI): 255.0 [M+H]⁺.

2.2k Benzooxazol-2-yl-(4-nitro-phenyl)-amine (table 1, Entry 11): solid; M.p.: 189–190°C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.93 (br s, 1H, NH), 8.77 (s, 1H), 8.15 (d, *J* = 8.90 Hz, 1H), 7.75 (d, *J* = 8.95 Hz, 1H), 7.49–7.40 (m, 2H), 7.28 (d, *J* = 3.10 Hz, 1H), 7.15 (t, *J* = 4.70 Hz, 1H), 7.04 (t, *J* = 5.51 Hz, 1H); Mass (ESI): 256.0 [M+H]⁺.

2.2l Benzooxazol-2-yl-(3,4-dichloro-phenyl)-amine (table 1, Entry 12): solid; M.p.: 217–218°C; IR (KBr, cm^{−1}): 3384, 3036, 1688, 1594, 1460, 1362, 1250, 747; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.30 (br s, 1H), 8.05–8.03 (m, 1H), 7.69–7.63 (m, 1H), 7.44–7.42 (m, 2H),

Table 1. Synthesis of *N*-phenyl-2-aminobenzazoles in absence of catalyst.

Entry	<i>o</i> -aminophenol/ <i>o</i> -aminothiophenol	Dithiocarbamate	Product	Yield (%)
1				88
2				92
3				84
4				86
5				85
6				90
7				82
8				85
9				94
10				90
11				84
12				88
13				86
14				92

7.37–7.25 (m, 2H), 7.22–7.18 (m, 1H), 7.06–7.03 (m, 1H); Mass (ESI): 278.9 [M+H]⁺.

2.2m *Benzo[1,3]dioxol-5-yl-benzooxazol-2-yl-amine* (table 1, Entry 13): solid; M.p.: 207–209°C; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.47 (br s, 1H, NH), 7.47–7.41 (m, 3H), 7.20–7.08 (m, 3H), 6.93–6.91 (d, *J* = 8.40 Hz, 1H), 6.00 (s, 2H); Mass (ESI): 255.2 [M+H]⁺.


2.2n *Benzothiazol-2-yl-pyridin-2-yl-amine* (table 1, Entry 14): Brown solid; M.p.: 233–234°C; ¹H NMR (400 MHz; DMSO-*d*₆): δ = δ 11.54 (s, 1H) 8.33 (d, 1H, *J* = 7.4 Hz) 7.88 (d, 1H, *J* = 7.7 Hz) 7.76 (t, 1H, *J* = 8.1, Hz), 7.61 (d, 1H, *J* = 7.9 Hz), 7.36 (t, 1H, *J* = 7.5 Hz), 7.20–7.15 (2H, m), 7.00 (t, 1H, *J* = 5.7 Hz); ¹³C NMR (50 MHz; CDCl₃): δ = 159.73, 152.00, 149.79, 146.92, 138.63, 131.99, 126.06, 122.33, 121.51, 119.45, 117.21, 111.58, Mass (ESI): 228 [M+H]⁺.

2.2o *N*-(5-Chloro-benzooxazol-2-yl)-*N'*-[6-methoxy-7-[3-(4-methyl-piperazin-1-yl)-propoxy]-quinazolin-4-yl]-benzene-1,4-diamine (**5a**): Colourless solid; M.p.: 174–176°C; IR (KBr, cm⁻¹): 3325, 2939, 2808, 1240,


1568, 1145, 798; ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.77 (s, 1H), 9.49 (s, 1H), 8.41 (s, 1H), 7.84 (s, 1H), 7.74 (s, 4H), 7.51 (d, *J* = 8.4 Hz, 2H), 7.16–7.13 (m, 2H), 4.16 (t, *J* = 6.0 Hz, 2H), 3.96 (s, 3H), 2.46–2.33 (m, 10H), 2.15 (s, 3H), 1.96–1.92 (m, 3H); ¹³C NMR (50 MHz, DMSO-*d*₆): δ 159.24, 156.42, 153.44, 152.92, 148.84, 146.82, 145.92, 144.17, 134.24, 134.01, 128.11, 123.46, 121.08, 117.98, 116.13, 109.93, 108.69, 107.72, 102.02, 66.70, 56.21, 54.71, 54.28, 52.65, 45.66, 40.12, 26.01; Mass (ESI): 574.3 [M+H]⁺.

2.2p *N*-[6-Methoxy-7-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-*N'*-oxazolo[4,5-*b*]pyridin-2-yl-benzene-1,4-diamine (**5b**): Yellow solid; IR (KBr, cm⁻¹): 3032, 2686, 1643, 1564, 1278; ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.12 (s, 1H), 9.75 (s, 1H), 8.74 (s, 1H), 8.25–8.24 (m, 1H), 8.09 (s, 1H), 7.89–7.70 (m, 5H), 7.25–7.13 (m, 2H), 4.26–4.23 (m, 2H), 3.98–3.71 (m, 13H), 2.45–2.17 (m, 2H); Mass (ESI): 528.3 [M+H]⁺.

2.2q *N*²-(5-Chloro-benzooxazol-2-yl)-*N*⁵-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-pyridine-2,5-diamine (**5c**): Light yellow solid; IR (KBr, cm⁻¹):



Scheme 1. Preparation of a series of *N*-aryl-2-amino-benzazoles.



Scheme 2. Synthesis of 4-aminoquinazoline derivatives from *N*-phenyl-2-aminobenzazoles.

3203, 2953, 2812, 1647, 1533, 1247, 794; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.45 (s, 1H), 9.62 (s, 1H), 8.73 (s, 1H), 8.44 (m, 1H), 8.26 (m, 2H), 7.84 (m, 1H), 7.57–7.55 (m, 2H), 7.21–7.18 (m, 2H), 4.21–4.18 (m, 2H), 3.97 (s, 3H), 3.59 (m, 4H), 2.67–2.32 (m, 4H), 1.97 (s, 2H); Mass (ESI): 562.3 $[\text{M}+\text{H}]^+$.
















2.2r *N*²-Benzooxazol-2-yl-*N*⁵-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-pyridine-2,5-diamine (5d): solid; IR (KBr, cm^{-1}): 3410, 2966, 2819, 1625, 1244; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 11.27 (s, 1H), 9.67 (s, 1H), 8.72–8.71 (s, 1H), 8.46 (m, 1H), 8.32–8.30 (m, 1H), 8.20–8.22 (m, 1H), 7.88 (s, 1H), 7.54–7.49 (m, 2H), 7.28–7.15 (m, 3H), 4.26–4.23 (m, 2H), 3.98–3.71 (m, 7H), 3.32 (s, 3H), 2.49–2.45 (m, 2H); Mass (ESI): 528.2 $[\text{M}+\text{H}]^+$.

2.2s *N*-(5-Chloro-benzooxazol-2-yl)-*N*'-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-benzene-1,4-diamine (5e): yellow solid; IR (KBr, cm^{-1}): 3423, 2943, 1674, 1514, 1234, 804; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 10.88 (s, 1H), 10.23 (s, 1H), 8.59 (s, 1H), 8.05 (s, 1H), 7.81–7.71 (m, 4H), 7.54–7.51 (m, 2H), 7.27 (s, 1H), 7.18–7.15 (m, 1H), 4.29–4.26 (m, 2H), 3.99 (s, 7H), 3.32 (s, 3H), 2.28 (m, 2H); Mass (ESI): 561.2 $[\text{M}+\text{H}]^+$.

3. Results and Discussions

We are particularly interested in the synthesis of *N*-aryl-2-aminobenzoxazoles and *N*-aryl-2-amino-benzothiazoles *via* a method suitable for large scale

Table 2. Assay of Aminoquinazolines with Aurora-A kinase data.

Sl. No.	Aminobenzoxazole derivatives	4-chloroquinazoline derivatives	Compound	Aurora-A % Inhibition @ 1 μM
1				95
2				97
3				98
4				97
5				85

preparations that will not use toxic starting materials or reagents. Herein, we report an efficient one-pot synthesis of *N*-aryl-2-aminobenzazoles by using *o*-aminophenol or *o*-aminothiophenol and substituted dithiocarbamate at room temperature (scheme 1). Unlike isothiocyanates, dithiocarbamates are not toxic, highly stable and easy to handle.¹⁶ They are easy to synthesize in large quantities using readily available substituted anilines.

The initial experiment involved a reaction between *o*-aminophenol and methyl phenyldithiocarbamate at room temperature yielded without using any catalyst the desired compound of *N*-phenyl-2-aminobenzoxazole. With these encouraging results we started our investigation with different dithiocarbamates and *o*-aminophenol/*o*-aminothiophenol and the results are listed in table 1. Several dithiocarbamates underwent the above conversion to form a series of *N*-aryl-2-amino- benzazoles. The reaction conditions are mild and the experimental procedure is simple. The products were formed in high yields (82–94%) regardless of the electronic properties of the dithiocarbamates.

Having demonstrated the generality of this reaction in between *o*-aminophenol/*o*-aminothiophenol and different dithiocarbamates, we further explored the possibility of synthesizing novel 4-aminoquinazoline class of compounds as Aurora kinase-A inhibitor. For this purpose 4-chloroquinazoline derivatives (**4**)¹⁷ were synthesized and treated with various *N*-aryl-2-aminobenzoxazoles/*N*-aryl-2-aminobenzothiazoles (**3**) to yield 4-aminoquinazoline derivatives (**5**) (scheme 2).

The novel 4-aminoquinazoline derivatives synthesized in this way were tested in Aurora kinase-A¹⁸ biological assay and the results are listed in table 2.

4. Conclusions

We have developed a general and efficient one-pot synthesis of *N*-phenyl-2-aminobenzazoles. Mild reaction condition, large scale synthesis, easy and quick isolation of the products and excellent yields are the main advantages of this procedure which makes this method an attractive and useful addition to the present methodologies. Application of this methodology has been demonstrated in synthesizing potent Aurora-A kinase inhibitors.

Supplementary Information

NMR, IR and mass spectra of the synthesized compounds are reported in Supplementary Information available at www.ias.ac.in/chemsci.

Acknowledgments

The authors are very thankful to analytical department of Dr. Reddy's Laboratories Ltd. for the spectral and analytical data.

References

- (a) Harris N V and Fenton G 2002 *World Pat.* 2002098426; (b) Darque A, Dumetre A, Hutter S, Casano G, Robin M, Pannecouque C and Azas N 2009 *Bioorg. Med. Chem. Lett.* **19** 5962
- Martin R E, Mohr P, Maerki H P, Guba W, Kuratli C, Gavelle O, Binggeli A, Bendels S, Alvarez-Sanchez R, Alker A, Polonchuk L and Christ A D 2009 *Bioorg. Med. Chem. Lett.* **19** 6106
- (a) Muro F, Limura S, Yoneda Y, Chiba J, Watanabe T, Masaki S, Takayama G, Yokoyama M, Takashi T, Nakayama A and Machinaga N 2009 *Bioorg. Med. Chem.* **17** 1232; (b) Song H, Oh S R, Lee H K, Han G, Kim J H, Chang H W, Doh K E, Rhee H K and Choo Y P 2010 *Bioorg. Med. Chem.* **18** 7580
- Potashman M H, Bready J, Coxon A, DeMelfi Jr. T M, DiPietro L, Doerr N, Elbaum D, Estrada J, Gallant P, Germain J, Gu Y, Harmange J C, Kaufman S A, Kendell R, Kim J L, Kumar G N, Long A M, Neervannan S, Patel V F, Polverino A, Rose P, Plas S ven der, Douglas W, Zanon R and Zhao H 2007 *J. Med. Chem.* **50** 4351
- Das J, Moquin R V, Lin J, Doweiko H M, Defex H F, Fung Q, Pang S, Pitt S, Shen D R, Schieven G L, Barrish J C and Wityak J 2003 *Bioorg. Med. Chem. Lett.* **13** 2587
- Liu C, Lin J, Pitt S, Zhang R F, Sack J S, Kieter S E, Kish K, Doweiko A M, Zhang H, Marathe P H, Trzaskos J, Mckinnon M, Dodd J H, Barrish J C, Schieven G L and Lefthenis K 2008 *Bioorg. Med. Chem. Lett.* **18** 1874
- Carpenter R D, Andrei M, Aina O H, Lau H Y, Lightstone F C, Liu R, Lam K S and Kurth M J 2009 *J. Med. Chem.* **52** 14
- (a) Ozaki S 1972 *Chem Rev.* **72** 457; (b) Ogura H, Mineo S and Nakagawa K 1981 *Chem. Pharm. Bull.* **29** 1518; (c) Tian Z, Plata D J, Wittenberger S J and Bhatia A V 2005 *Tetrahedron Lett.* **46** 8341
- Qian X H, Li Z B, Song G H and Li Z 2001 *J. Chem. Res. Synop.* **4** 138
- Ogura H, Mineo S and Nakagawa K 1981 *Chem. Pharm. Bull.* **29** 1518
- Cee V J and Downing N S 2006 *Tetrahedron Lett.* **47** 3747
- Yella R and Patel B K 2010 *J. Comb. Chem.* **12** 754
- (a) Qui J W, Zhang X G, Tang R Y, Zhong P and Li J H 2009 *Ad. Synth. Catal.* **351** 2319; (b) Wang J, Peng F, Jiang J L, Lu Z J, Wang L Y, Bai J and Pan Y 2008 *Tetrahedron Lett.* **49** 467; (c) Joyce L L, Evindar G and Batey R A 2004 *Chem. Comm.* 446; (d) Benedi C, Bravo F, Uriz P, Fernández E, Claver C and Castellón S 2003 *Tetrahedron Lett.* **44** 6073
- Joyce L L and Batey R A 2009 *Org. Lett.* **11** 2792

15. (a) Das P, Kirankumar C, Nareshkumar K, Innus Md, Iqbal J and Srinivas N 2008 *Tetrahedron Lett.* **49** 922; (b) Nareshkumar K, Sreeramamurthy K, Sandananda P, Mukkanti K and Das P 2010 *Tetrahedron Lett.* **51** 899
16. (a) Azizi N, Ebrahimi F, Aakbari E, Aryanasab F and Saidi M R 2007 *Synthesis* 2797; (b) Azizi N, Aryanasab F, Torkiyan L, Ziyaei A and Saidi M R 2006 *J. Org. Chem.* **71** 3634; (c) Azizi N, Aryanasab F and Saidi M R 2006 *Org. Lett.* **8** 5275; (d) Wang Y Q, Ge Z M, Hou X L, Cheng T M and Li R T 2004 *Synthesis* 675; (e) Salvatore R N, Sahab S and Jung K 2001 *Tetrahedron Lett.* **42** 2055
17. (a) Ple P A, Green T P, Hennequin L F, Curwen J, Fennel M, Allen J, van der Bremp C L and Costello G 2004 *J. Med. Chem.* **47** 871; (b) Sreeramamurthy K, Ashok E, Mahendar V, Santoshkumar G and Das P 2010 *Synlett.* 721
18. Pollard J R and Mortimore M 2009 *J. Med. Chem.* **52** 2629